Press Releases Torii Pharmaceutical Co., Ltd.

Equities

4551

JP3635800000

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-06-26 EDT			5-day change	1st Jan Change
3,750 ^JPY	+0.81%		+5.78%	+5.49%

05-15	Verrica Pharmaceuticals Amends Licensing Agreement With Torii Pharmaceutical for Phase 3 Trial of Ycanth	MT
05-15	Verrica Pharmaceuticals Inc. Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study Ycanth for the Treatment of Common Warts	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Torii Pharmaceutical : JT Receives Manufacturing and Marketing Approval of VTAMA® Cream 1% for the Treatment of Atopic Dermatitis and Plaque Psoriasis in Japan	06-24	PU
Torii Pharmaceutical : Positive Top line Results of Phase 3 Clinical Study (Comparative Study) of JTE 061 (tapinarof) Cream, Aryl hydrocarbon Receptor (AhR) agonist, in Pediatric Patients with Atopic Dermatitis in Japan	05-31	PU
Torii Pharmaceutical - Top-line Results of Phase 3 Clinical Study of TO-208 for the Treatment of Molluscum Contagiosum in Japan	12-18	AQ
Verrica Pharmaceuticals Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208	12-18	AQ
Torii Pharmaceutical : Top-line Results of Phase 3 Clinical Study of TO-208 for the Treatment of Molluscum Contagiosum in Japan	12-15	PU
Torii Pharmaceutical : Signing of an Agreement for the Exclusive Development and Commercialization of GRAZAX®,an Allergen Immunotherapy (Sublingual Immunotherapy) Drug for Grass Pollinosis in Japan	12-12	PU
Torii Pharmaceutical : Financial Results for the First Nine Months of Fiscal Year Ending December 2023	23-10-31	PU
Torii Pharmaceutical - JT Files New Drug Application of JTE-061 Cream, Aryl hydrocarbon Receptor agonist, for the Treatment of Atopic Dermatitis and Plaque Psoriasis in Japan	23-09-18	AQ
Torii Pharmaceutical : JT Files New Drug Application of JTE-061 Cream,Aryl hydrocarbon Receptor (AhR) agonist,for the Treatment of Atopic Dermatitis and Plaque Psoriasis in Japan	23-09-15	PU
Torii Pharmaceutical : Financial Results for the First Three Months of Fiscal Year Ending December 2023	23-04-28	PU
Torii Pharmaceutical : Views on Report from ISS, a Proxy Advisory Firm, On Proposals for ’s General Meeting of Shareholders	23-03-16	PU
Torii Pharmaceutical : Notice of the Opinion of the Board of Directors Regarding the Shareholder Proposal	23-02-17	PU
Torii has announced Medium-Term Management Plan 2023-2025	23-02-13	AQ
Torii Pharmaceutical : has announced Medium-Term Management Plan 2023-2025	23-02-10	PU
Torii Pharmaceutical : Financial Results for the Fiscal Year 2022, Ended December 31, 2022	23-02-10	PU
Torii Pharmaceutical : has entered into License Agreement with Nogra Pharma Limited to Develop & Commercialize NAC-GED-0507 in Japan	23-01-22	PU
Torii Pharmaceutical : Financial Results for the First Nine Months of Fiscal Year Ending December 2022	22-10-31	PU
Torii Pharmaceutical Co., Ltd. - Positive Top-line Results of Phase 3 Clinical Study of JTE-061 Cream, Aryl Hydrocarbon Receptor Agonist, in Patients with Plaque Psoriasis in Japan	22-09-16	AQ
Torii Pharmaceutical : Positive Top-line Results of Phase 3 Clinical Study (Comparative Study) of JTE-061 (tapinarof) Cream, Aryl Hydrocarbon Receptor (AhR) Agonist, in Patients with Plaque Psoriasis in Japan（PDF）	22-09-16	PU
Torii Pharmaceutical : Financial Results for the First Six Months of Fiscal Year Ending December 2022	22-07-29	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Torii Pharmaceutical Co., Ltd.

Equities

4551

JP3635800000

Press Releases

Filters